154 related articles for article (PubMed ID: 29774123)
1. The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis.
Shimonosono M; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kijima Y; Kurahara H; Kita Y; Mori S; Sasaki K; Omoto I; Maemura K; Uenosono Y; Ishigami S; Natsugoe S
Oncotarget; 2018 Apr; 9(31):22069-22078. PubMed ID: 29774123
[TBL] [Abstract][Full Text] [Related]
2. HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.
Wei L; Tang L; Chang H; Huo S; Li Y
Hum Cell; 2020 Jan; 33(1):116-122. PubMed ID: 31552567
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
[TBL] [Abstract][Full Text] [Related]
4. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
[TBL] [Abstract][Full Text] [Related]
5. High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.
Niu Y; Wang W; Jiang X; Huang Y; Yan S; Jiang Y
Jpn J Clin Oncol; 2022 Jul; 52(7):759-765. PubMed ID: 35348687
[TBL] [Abstract][Full Text] [Related]
6. Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer.
Zhang X; Qin Y; Chen X; Xiong M; Shu S
Technol Cancer Res Treat; 2024; 23():15330338241240683. PubMed ID: 38613340
[No Abstract] [Full Text] [Related]
7. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
[TBL] [Abstract][Full Text] [Related]
8. Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 Possesses Prognostic Significance and Promotes Progression of Papillary Thyroid Cancer.
Niu Y; Huang Y; Dong A; Sun Y
Int J Gen Med; 2022; 15():1509-1516. PubMed ID: 35210824
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HHLA2 and CD8 Immunohistochemical Expression in Colorectal Carcinoma and Their Prognostic Significance.
Gawesh ZM; Ibrahim EM; ElKalla HMHR; Awad AAH; Mohamed MA
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4309-4319. PubMed ID: 38156868
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of HHLA2 expression in solid tumors: A meta-analysis based on the Chinese population.
Zhang C; Xu J; Ye J; Zhang X
Medicine (Baltimore); 2021 Jul; 100(30):e26789. PubMed ID: 34397730
[TBL] [Abstract][Full Text] [Related]
11. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.
Ying H; Xu J; Zhang X; Liang T; Bai X
EBioMedicine; 2022 May; 79():103987. PubMed ID: 35439678
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment.
Luo M; Lin Y; Liang R; Li Y; Ge L
J Inflamm Res; 2021; 14():4217-4228. PubMed ID: 34483677
[TBL] [Abstract][Full Text] [Related]
13. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of HHLA2 as a Novel Therapeutic Target for Colorectal Cancer.
Wang H; An Z; Liu Y; Ding G; Deng G; Ji C; Gong Y
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38299402
[TBL] [Abstract][Full Text] [Related]
15. HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma.
Xu Y; Huang Z; Yu X; Li Z; Zheng L; Xu J
Biologics; 2021; 15():329-341. PubMed ID: 34413629
[TBL] [Abstract][Full Text] [Related]
16. Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
Nishihara D; Kijima T; Arai K; Kamai T
Int Urol Nephrol; 2023 Apr; 55(4):867-874. PubMed ID: 36598731
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma.
Zhu Z; Dong W
Onco Targets Ther; 2018; 11():1563-1570. PubMed ID: 29593422
[TBL] [Abstract][Full Text] [Related]
18. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells.
Arigami T; Uenosono Y; Hirata M; Yanagita S; Ishigami S; Natsugoe S
Cancer Sci; 2011 May; 102(5):1019-24. PubMed ID: 21251161
[TBL] [Abstract][Full Text] [Related]
19. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.
Janakiram M; Chinai JM; Fineberg S; Fiser A; Montagna C; Medavarapu R; Castano E; Jeon H; Ohaegbulam KC; Zhao R; Zhao A; Almo SC; Sparano JA; Zang X
Clin Cancer Res; 2015 May; 21(10):2359-66. PubMed ID: 25549724
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
